نتائج بحث المؤلف

1

Monoclonal B-cell lymphocytosis حسب Andy C. Rawstron

منشور في 2009

احصل على النص الكامل احصل على النص الكامل
Revisão

أضف إلى المفضلة

محفوظ في:
2

Assessment of minimal residual disease in myeloma and the need for a consensus approach حسب Andy C. Rawstron, Bruno Paiva, Maryalice Stetler‐Stevenson

منشور في 2015

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
3

Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria حسب Stephen J. Richards, Andy C. Rawstron, Peter Hillmen

منشور في 2000

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
4

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis حسب Quentin A. Hill, Andy C. Rawstron, Ruth M. de Tute, Roger G. Owen

منشور في 2014

احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
5

Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management حسب Tait D. Shanafelt, Paolo Ghia, Mark C. Lanasa, Ola Landgren, Andy C. Rawstron

منشور في 2010

احصل على النص الكامل
Revisão

أضف إلى المفضلة

محفوظ في:
6

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis حسب Shouvik Dass, Andy C. Rawstron, Edward M Vital, Karen Henshaw, Dennis McGonagle, Paul Emery

منشور في 2008

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
7

$Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia$

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia حسب Ben Kennedy, Andy C. Rawstron, CG Carter, Mary Ryan, Kevin Speed, Guy Lucas, Peter Hillmen

منشور في 2002

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
8

Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab حسب Dennis McGonagle, Ai Lyn Tan, Julie Madden, Andy C. Rawstron, Abdul Rehman, Paul Emery, Stanley Thomas

منشور في 2007

احصل على النص الكامل احصل على النص الكامل
Carta

أضف إلى المفضلة

محفوظ في:
9

Different biology and clinical outcome according to the absolute numbers of clonal B‐cells in monoclonal B‐cell lymphocytosis (MBL) حسب Andy C. Rawstron, Tait D. Shanafelt, Mark C. Lanasa, Ola Landgren, Curtis A. Hanson, Alberto Órfão, Peter Hillmen, Paolo Ghia

منشور في 2010

احصل على النص الكامل احصل على النص الكامل
Revisão

أضف إلى المفضلة

محفوظ في:
10

Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition حسب Gururaj Arumugakani, Sophie Stephenson, Darren J. Newton, Andy C. Rawstron, Paul Emery, Gina M. Doody, Dennis McGonagle, Reuben Tooze

منشور في 2017

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
11

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus حسب Md Yuzaiful Md Yusof, Daniel S. Shaw, Yasser M. El‐Sherbiny, Emma Dunn, Andy C. Rawstron, Paul Emery, Edward M Vital

منشور في 2017

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
12

B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursors حسب Andy C. Rawstron, Faith E. Davies, Roger G. Owen, Anne English, Guy Pratt, J. A. Child, Andrew Jack, Gareth J. Morgan

منشور في 1998

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
13

Diagnostic criteria for monoclonal B‐cell lymphocytosis حسب Gerald E. Marti, Andy C. Rawstron, Paolo Ghia, Peter Hillmen, Richard S. Houlston, Neil E. Kay, Thérèse Aurran Schleinitz, Neil E. Caporaso

منشور في 2005

احصل على النص الكامل
Revisão

أضف إلى المفضلة

محفوظ في:
14

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition حسب Maryalice Stetler‐Stevenson, Bruno Paiva, Lloyd M. Stoolman, Pei Lin, Jeffrey L. Jorgensen, Alberto Órfão, Jacques J. M. van Dongen, Andy C. Rawstron

منشور في 2015

احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
15

Minimal residual disease is an independent predictor for 10-year survival in CLL حسب Marwan Kwok, Andy C. Rawstron, Abraham Varghese, Paul Evans, Sheila J.M. O’Connor, Chi Doughty, Darren J. Newton, Paul Moreton, Peter Hillmen

منشور في 2016

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
16

CD4+CD25+FoxP3+ regulatory T cells are increased whilst CD3+CD4−CD8−αβTCR+ Double Negative T cells are... حسب Sylvia Feyler, M von Lilienfeld-Toal, Sarah Jarmin, Lee Marles, Andy C. Rawstron, A. John Ashcroft, Roger G. Owen, Peter J. Selby, Gordon Cook

منشور في 2009

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
17

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion حسب Andy C. Rawstron, Martin Yuille, Julie Fuller, Matthew Cullen, Ben Kennedy, Stephen J. Richards, Andrew Jack, Estella Matutes, Daniel Catovsky, Peter Hillmen, Richard S. Houlston

منشور في 2002

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
18

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting حسب Maria Arroz, Neil Came, Pei Lin, Weina Chen, Constance M. Yuan, Anand S. Lagoo, Mariela Monreal, Ruth de Tute, Jo‐Anne Vergilio, Andy C. Rawstron, Bruno Paiva

منشور في 2015

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
19

IgM myeloma: a rare entity characterized by a CD20−CD56−CD117− immunophenotype and the t(11;14) حسب Sylvia Feyler, Sheila J.M. O’Connor, Andy C. Rawstron, Chezhian Subash, Fiona M. Ross, Guy Pratt, Mark T. Drayson, John Ashcroft, Gordon Cook, Roger G. Owen

منشور في 2008

احصل على النص الكامل احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:
20

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases حسب Md Yuzaiful Md Yusof, Edward M Vital, Damien McElvenny, E. Hensor, Sudipto Das, Shouvik Dass, Andy C. Rawstron, Maya H Buch, Paul Emery, Sinisa Savic

منشور في 2019

احصل على النص الكامل
Artigo

أضف إلى المفضلة

محفوظ في:

نتائج البحث - Andy C. Rawstron

Monoclonal B-cell lymphocytosis حسب Andy C. Rawstron

Assessment of minimal residual disease in myeloma and the need for a consensus approach حسب Andy C. Rawstron, Bruno Paiva, Maryalice Stetler‐Stevenson

Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria حسب Stephen J. Richards, Andy C. Rawstron, Peter Hillmen

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis حسب Quentin A. Hill, Andy C. Rawstron, Ruth M. de Tute, Roger G. Owen

Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management حسب Tait D. Shanafelt, Paolo Ghia, Mark C. Lanasa, Ola Landgren, Andy C. Rawstron

Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis حسب Shouvik Dass, Andy C. Rawstron, Edward M Vital, Karen Henshaw, Dennis McGonagle, Paul Emery

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia حسب Ben Kennedy, Andy C. Rawstron, CG Carter, Mary Ryan, Kevin Speed, Guy Lucas, Peter Hillmen

Successful treatment of resistant scleroderma-associated interstitial lung disease with rituximab حسب Dennis McGonagle, Ai Lyn Tan, Julie Madden, Andy C. Rawstron, Abdul Rehman, Paul Emery, Stanley Thomas

Different biology and clinical outcome according to the absolute numbers of clonal B‐cells in monoclonal B‐cell lymphocytosis (MBL) حسب Andy C. Rawstron, Tait D. Shanafelt, Mark C. Lanasa, Ola Landgren, Curtis A. Hanson, Alberto Órfão, Peter Hillmen, Paolo Ghia

Early Emergence of CD19-Negative Human Antibody-Secreting Cells at the Plasmablast to Plasma Cell Transition حسب Gururaj Arumugakani, Sophie Stephenson, Darren J. Newton, Andy C. Rawstron, Paul Emery, Gina M. Doody, Dennis McGonagle, Reuben Tooze

Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus حسب Md Yuzaiful Md Yusof, Daniel S. Shaw, Yasser M. El‐Sherbiny, Emma Dunn, Andy C. Rawstron, Paul Emery, Edward M Vital

B‐lymphocyte suppression in multiple myeloma is a reversible phenomenon specific to normal B‐cell progenitors and plasma cell precursors حسب Andy C. Rawstron, Faith E. Davies, Roger G. Owen, Anne English, Guy Pratt, J. A. Child, Andrew Jack, Gareth J. Morgan

Diagnostic criteria for monoclonal B‐cell lymphocytosis حسب Gerald E. Marti, Andy C. Rawstron, Paolo Ghia, Peter Hillmen, Richard S. Houlston, Neil E. Kay, Thérèse Aurran Schleinitz, Neil E. Caporaso

Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition حسب Maryalice Stetler‐Stevenson, Bruno Paiva, Lloyd M. Stoolman, Pei Lin, Jeffrey L. Jorgensen, Alberto Órfão, Jacques J. M. van Dongen, Andy C. Rawstron

Minimal residual disease is an independent predictor for 10-year survival in CLL حسب Marwan Kwok, Andy C. Rawstron, Abraham Varghese, Paul Evans, Sheila J.M. O’Connor, Chi Doughty, Darren J. Newton, Paul Moreton, Peter Hillmen

Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion حسب Andy C. Rawstron, Martin Yuille, Julie Fuller, Matthew Cullen, Ben Kennedy, Stephen J. Richards, Andrew Jack, Estella Matutes, Daniel Catovsky, Peter Hillmen, Richard S. Houlston

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting حسب Maria Arroz, Neil Came, Pei Lin, Weina Chen, Constance M. Yuan, Anand S. Lagoo, Mariela Monreal, Ruth de Tute, Jo‐Anne Vergilio, Andy C. Rawstron, Bruno Paiva

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases حسب Md Yuzaiful Md Yusof, Edward M Vital, Damien McElvenny, E. Hensor, Sudipto Das, Shouvik Dass, Andy C. Rawstron, Maya H Buch, Paul Emery, Sinisa Savic

أدوات البحث:

موضوعات ذات صلة